story of the week
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neurotherapeutics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Neurotherapeutics 2020 Jan 01;17(1)200-207, M Clerico, SF De Mercanti, A Signori, M Iudicello, C Cordioli, E Signoriello, G Lus, S Bonavita, L Lavorgna, GT Maniscalco, E Curti, L Lorefice, E Cocco, V Nociti, M Mirabella, D Baroncini, G Mataluni, D Landi, M Petruzzo, R Lanzillo, I Gandoglia, A Laroni, R Frangiamore, A Sartori, P Cavalla, G Costantini, MP Sormani, R CapraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.